Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: Tolerance and activity in ovarian cancer

Tamar Safra, Susan Jeffers, Joan Sorich, Franco M. Muggia*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Nine patients with cancers of gynecologic or peritoneal origin were treated with a combination of gemcitabine, amifostine and cisplatin (GAP). The rationale of including amifostine was primarily related to the amount of prior cisplatin the patients had received and the need to protect against additional neurotoxicity. After encouraging activity and tolerance had been noted, entry of three patients with severely compromised bone marrow was also allowed. These three patients required dose reductions and did not tolerate treatment more often than every other week, but nevertheless, one of them experienced a partial response lasting 9 months. Another two of the nine patients had CA125 decreases fulfilling Rustin's definition of response and one had elimination of ascites. Future studies of this combination are warranted.

Original languageEnglish
Pages (from-to)511-514
Number of pages4
JournalAnti-Cancer Drugs
Volume9
Issue number6
StatePublished - 1998

Funding

FundersFunder number
National Cancer InstituteR01CA048780

    Keywords

    • Amifostine
    • Cisplatin
    • GAP
    • Gemcitabine
    • Gynecologic cancer
    • Ovarian cancer
    • Peritoneal cancer
    • Pretreatment

    Fingerprint

    Dive into the research topics of 'Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: Tolerance and activity in ovarian cancer'. Together they form a unique fingerprint.

    Cite this